These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 36136322)

  • 1. Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care-Checking CHEK2.
    Bychkovsky BL; Agaoglu NB; Horton C; Zhou J; Yussuf A; Hemyari P; Richardson ME; Young C; LaDuca H; McGuinness DL; Scheib R; Garber JE; Rana HQ
    JAMA Oncol; 2022 Nov; 8(11):1598-1606. PubMed ID: 36136322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast and colorectal cancer risks among over 6,000 CHEK2 pathogenic variant carriers: A comparison of missense versus truncating variants.
    Mundt E; Mabey B; Rainville I; Ricker C; Singh N; Gardiner A; Manley S; Slavin T
    Cancer Genet; 2023 Nov; 278-279():84-90. PubMed ID: 37839337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High risk of breast cancer in women with biallelic pathogenic variants in CHEK2.
    Rainville I; Hatcher S; Rosenthal E; Larson K; Bernhisel R; Meek S; Gorringe H; Mundt E; Manley S
    Breast Cancer Res Treat; 2020 Apr; 180(2):503-509. PubMed ID: 31993860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes.
    Gallagher S; Hughes E; Wagner S; Tshiaba P; Rosenthal E; Roa BB; Kurian AW; Domchek SM; Garber J; Lancaster J; Weitzel JN; Gutin A; Lanchbury JS; Robson M
    JAMA Netw Open; 2020 Jul; 3(7):e208501. PubMed ID: 32609350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in cancer prevalence among CHEK2 carriers identified via multi-gene panel testing.
    Sutcliffe EG; Stettner AR; Miller SA; Solomon SR; Marshall ML; Roberts ME; Susswein LR; Arvai KJ; Klein RT; Murphy PD; Hruska KS
    Cancer Genet; 2020 Aug; 246-247():12-17. PubMed ID: 32805687
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Brock P; Liynarachchi S; Nieminen TT; Chan C; Kohlmann W; Stout LA; Yao S; La Greca A; Jensen KE; Kolesar JM; Salhia B; Gulhati P; Hicks JK; Ringel MD
    Thyroid; 2024 Apr; 34(4):477-483. PubMed ID: 38279823
    [No Abstract]   [Full Text] [Related]  

  • 7. The heterogeneous cancer phenotype of individuals with biallelic germline pathogenic variants in CHEK2.
    Hinić S; Cybulski C; Van der Post RS; Vos JR; Schuurs-Hoeijmakers J; Brugnoletti F; Koene S; Vreede L; van Zelst-Stams WAG; Kets CM; Haadsma M; Spruijt L; Wevers MR; Evans DG; Wimmer K; Schnaiter S; Volk AE; Möllring A; de Putter R; Soikkonen L; Kahre T; Tooming M; de Jong MM; Vaz F; Mensenkamp AR; Genuardi M; Lubinski J; Ligtenberg M; Hoogerbrugge N; de Voer RM
    Genet Med; 2024 May; 26(5):101101. PubMed ID: 38362852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer risk is similar for CHEK2 founder and non-founder mutation carriers.
    Leedom TP; LaDuca H; McFarland R; Li S; Dolinsky JS; Chao EC
    Cancer Genet; 2016 Sep; 209(9):403-407. PubMed ID: 27751358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis.
    Han FF; Guo CL; Liu LH
    DNA Cell Biol; 2013 Jun; 32(6):329-35. PubMed ID: 23713947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Breast Cancer Risk Assessment for
    Gallagher S; Hughes E; Kurian AW; Domchek SM; Garber J; Probst B; Morris B; Tshiaba P; Meek S; Rosenthal E; Roa B; Slavin TP; Wagner S; Weitzel J; Gutin A; Lanchbury JS; Robson M
    JCO Precis Oncol; 2021 Jun; 5():. PubMed ID: 34322652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative Analysis of Germline Rare Variants in Clear and Non-Clear Cell Renal Cell Carcinoma.
    Han S; Camp SY; Chu H; Collins R; Gillani R; Park J; Bakouny Z; Ricker CA; Reardon B; Moore N; Kofman E; Labaki C; Braun D; Choueiri TK; AlDubayan SH; Van Allen EM
    medRxiv; 2023 Jan; ():. PubMed ID: 36712083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing Cancer Risk Management between Females with Truncating
    Garmendia D; Weidner A; Venton L; Pal T
    Genes (Basel); 2024 Jul; 15(7):. PubMed ID: 39062660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiling of the genetic features of patients with breast, ovarian, colorectal and extracolonic cancers: Association to CHEK2 and PALB2 germline mutations.
    Infante M; Arranz-Ledo M; Lastra E; Olaverri A; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
    Clin Chim Acta; 2024 Jan; 552():117695. PubMed ID: 38061684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of bladder or renal cancer in patients with CHEK2 mutations.
    Złowocka-Perłowska E; Dębniak T; Słojewski M; van de Wetering T; Tołoczko-Grabarek A; Cybulski C; Scott RJ; Lubiński J
    PLoS One; 2021; 16(9):e0257132. PubMed ID: 34499690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-evaluating cancer risks associated with the CHEK2 p.Ser428Phe Ashkenazi Jewish founder pathogenic variant.
    Laitman Y; Nielsen SM; Hatchell KE; Truty R; Bernstein-Molho R; Esplin ED; Friedman E
    Fam Cancer; 2022 Jul; 21(3):305-308. PubMed ID: 34622392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors.
    AlDubayan SH; Pyle LC; Gamulin M; Kulis T; Moore ND; Taylor-Weiner A; Hamid AA; Reardon B; Wubbenhorst B; Godse R; Vaughn DJ; Jacobs LA; Meien S; Grgic M; Kastelan Z; Markt SC; Damrauer SM; Rader DJ; Kember RL; Loud JT; Kanetsky PA; Greene MH; Sweeney CJ; Kubisch C; Nathanson KL; Van Allen EM; Stewart DR; Lessel D;
    JAMA Oncol; 2019 Apr; 5(4):514-522. PubMed ID: 30676620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
    Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
    Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Gene Variant Type and Location with Breast Cancer Risk in the General Population.
    Akamandisa MP; Boddicker NJ; Yadav S; Hu C; Hart SN; Ambrosone C; Anton-Culver H; Auer PL; Bodelon C; Burnside ES; Chen F; Eliassen HA; Goldgar DE; Haiman C; Hodge JM; Huang H; John EM; Karam R; Lacey JV; Lindstroem S; Martinez E; Na J; Neuhausen SL; O'Brien KM; Olson JE; Pal T; Palmer JR; Patel AV; Pesaran T; Polley EC; Richardson ME; Ruddy K; Sandler DP; Teras LR; Trentham-Dietz A; Vachon CM; Weinberg C; Winham SJ; Yao S; Zirpoli G; Kraft P; Weitzel JN; Domchek SM; Couch FJ; Nathanson KL
    medRxiv; 2024 Oct; ():. PubMed ID: 39417132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population.
    Shaag A; Walsh T; Renbaum P; Kirchhoff T; Nafa K; Shiovitz S; Mandell JB; Welcsh P; Lee MK; Ellis N; Offit K; Levy-Lahad E; King MC
    Hum Mol Genet; 2005 Feb; 14(4):555-63. PubMed ID: 15649950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.